Introduction to ASCO 2025 Lung Cancer Immunotherapy Updates At the MOASC/ANCO Immuno-Oncology Symposium held on September 6, 2025, in Marina…
Browsing: SCLC
Tarlatamab Phase 3 Results SCLC ASCO 2025 The tarlatamab phase 3 results for SCLC, shared at ASCO 2025, showed a…
On September 12, 2024, the U.S. Food and Drug Administration (FDA) approved Tecentriq Hybreza, the first subcutaneous (SC) formulation of…
… Introduction Small cell lung cancer (SCLC) is notoriously aggressive and challenging to treat, with current therapies often providing limited…